Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Food and Drug Administration approval of a fifth acellular pertussis vaccine for use among infants and young children--United States, 2002.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2002 Jul 5;51(26):574.

2.

FDA approval of a second acellular pertussis vaccine for use among infants and young children.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 1997 Feb 7;46(5):110-1.

3.

FDA approval of a fourth acellular pertussis vaccine for use among infants and young children.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 1998 Nov 6;47(43):934-6.

4.

Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)

[No authors listed]

MMWR Recomm Rep. 1997 Mar 28;46(RR-7):1-25. Erratum in: MMWR Morb Mortal Wkly Rep 1997 Aug 1;46(30):706.

6.

Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).

Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, Mijalski CM, Tiwari T, Weston EJ, Cohn AC, Srivastava PU, Moran JS, Schwartz B, Murphy TV; Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2006 Mar 24;55(RR-3):1-34.

7.

FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 1996 Nov 15;45(45):993-5.

8.

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.

Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.

Pediatrics. 2005 Aug;116(2):e285-94.

PMID:
16061582
10.
11.
13.
14.

Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose.

Liang J, Wallace G, Mootrey G.

MMWR Morb Mortal Wkly Rep. 2015 Sep 4;64(34):948-9. doi: 10.15585/mmwr.mm6434a5.

15.

FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2003 Mar 14;52(10):203-4. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Apr 25;52(16):379.

17.

Potential impact of acceleration of the pertussis vaccine primary series for infants.

Shinall MC Jr, Peters TR, Zhu Y, Chen Q, Poehling KA.

Pediatrics. 2008 Nov;122(5):1021-6. doi: 10.1542/peds.2007-3025.

PMID:
18977982
18.

Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.

America Academy of Pediatrics Commitee on Infectious Diseases.

Pediatrics. 2006 Mar;117(3):965-78. Epub 2005 Dec 28.

PMID:
16382131
20.

Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).

Murphy TV, Slade BA, Broder KR, Kretsinger K, Tiwari T, Joyce PM, Iskander JK, Brown K, Moran JS; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2008 May 30;57(RR-4):1-51. Review. Erratum in: MMWR Morb Mortal Wkly Rep. 2008 Jul 4;57(26):723.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk